Lessons to be learned from TELK--Questions(s) for board.
When handicaping a drug's chance of sucess, I consider it a positive to have a pharma or large biotech as a partner in drug development. My thinking is that it is good to have a second set of eyes evaluate the data. If pharma/large biotech views the data high enough quality to get through the FDA, then they fund the project.
Is there data to back up my impression? Specifically, do partnered drugs have a higher sucess rate in Phase III?
Regarding the converse.
As a general rule of biotech investing, what does it say when a biotech has an unpartnered drug in phase III. Specifically, should it have been a warning sign seeing that TELK's drug was unpartnered in phase III?
Happy New Year!
biophud
